Pandemic heightens regulatory performance importance for life science companies

New challenges and best practices in regulatory information management (RIM)

playing game on iPad screenRegulatory performance was a key issue for life science companies even before the COVID-19 pandemic. Now, given the need to petition health authorities for variations to registrations and clinical protocols, as well as opportunities for Emergency Use Authorizations, life sciences companies are placing even more burden on their regulatory teams.

Gens & Associates, a global life science consulting and benchmarking firm specializing in strategic planning, RIM programs, benchmarking, and organizational performance, conducts a biennial survey tracking industry performance, technology trends and key change drivers for regulatory divisions. It’s 2020 World Class Regulatory Information Management study was conducted between February and April of this year. In this podcast, Steve Gens, managing partner of Gens & Associates, and John Cassimatis, Grant Thornton’s Life Sciences Business Consulting Sector leader, discuss recent survey findings and what life science companies are doing today to improve regulatory performance.

John CassimatisJohn Cassimatis
Managing Director
Operations Transformation
T +1 215 558 6533

Steve GensSteve Gens
Managing Partner
Gens & Associates
T +1 267 164 0935